Search Medical Condition
Please enter condition
Please choose location
 

Glendale, California Clinical Trials

A listing of Glendale, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (870) clinical trials

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric patients (age 7 to 11 years)

Phase

0.0 miles

Learn More »

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).

Phase

0.0 miles

Learn More »

Phase 1 TAK-041 First-in-Human Safety Tolerability and Pharmacokinetics Study

The drug being tested in this study is called TAK-041. TAK-041 is being tested to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of TAK-041 in healthy participants. The study will enroll approximately 40 participants. The study is composed of 2 parts. Part 1 (single-rising dose ...

Phase

0.0 miles

Learn More »

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

TAK-071 is being tested to find a safe and well-tolerated dose in healthy participants (non-Japanese and Japanese) and participants with MCI or mild AD (non-Japanese). The study will enroll approximately 186 participants. The study consists of 4 parts: Single-rising dose (SRD) part (Cohorts 1-6, and 18-22), multiple-rising dose (MRD) part ...

Phase

0.0 miles

Learn More »

ITI-007 for the Treatment of Agitation in Patients With Dementia Including Alzheimer's Disease

This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.

Phase

0.0 miles

Learn More »

A Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of E2027 in Healthy Subjects

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of multiple ascending oral doses of E2027 in healthy participants.

Phase

0.0 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with DD-CKD

Phase

0.0 miles

Learn More »

TAK-071 Scopolamine-Induced Cognitive Impairment Study

The drug being tested in this study is called TAK-071. This study will look at the effect of a single oral dose of TAK-071, a novel muscarinic acetylcholine receptor 1 positive allosteric modulator, on scopolamine-induced deficits in cognitive function in healthy adult male participants. The study consists of two parts: ...

Phase

0.0 miles

Learn More »

A Study to Investigate Safety Tolerability and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of JNJ-56136379 in healthy Japanese adult participants following oral administration of single doses from 25 milligram (mg) up to 600 mg, in fasted conditions.

Phase

0.0 miles

Learn More »

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Phase

0.0 miles

Learn More »